Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496808 · ClinicalTrials.gov registry record · NA
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 69
- Enrollment target
NCT00496808: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00496808 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496808, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 69 participants
- Enrollment target
Study Summary
Primary Objectives: * To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS) * To evaluate the effect of a single dose of Herceptin on the apoptotic index of Her-2/neu over-expressing DCIS
Interventions
- DRUG Herceptin (Trastuzumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496808
The ClinicalTrials.gov registry entry for NCT00496808 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Herceptin (Trastuzumab) is the first listed.
NCT00496808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496808 about?
NCT00496808 is a clinical study titled "Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast". Primary Objectives: * To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS) * To evaluate the effect of a single dose of Herceptin on the apoptotic index of Her-2/neu over-expressing DCIS
What is the current status of trial NCT00496808?
This trial is currently completed. It is a NA study. The enrollment target is 69 participants. The study started on 2005-03. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00496808?
The interventions under investigation include: Herceptin (Trastuzumab) (DRUG).
Who is sponsoring clinical trial NCT00496808?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.